Immunology & Cancer Immunotherapy (ICI)

免疫学

• 批准号: 8804020
• 负责人: Charles L. Sentman
• 金额: $ 7万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-04 至 2019-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8804020
• 关键词: Affect; Area; Award; Basic Science; Cancer Center Support Grant; Cancer Patient; Cell Therapy; Clinical; Clinical Research; Clinical Trials; Collaborations; Conduct Clinical Trials; Development; Faculty; Funding; Glioblastoma; Goals; Grant; Hematologist; Hematopoietic Stem Cell Transplantation; Immune; Immune system; Immunity; Immunobiology; Immunologist; Immunology; Immunotherapy; Joints; Journals; Large Intestine Carcinoma; Leukocytes; Malignant Neoplasms; Mission; Multiple Myeloma; Oncologist; Outcome; Patients; Peer Review; Proteins; Publications; Publishing; Regulation; Renal Cell Carcinoma; Reporting; Research; Research Personnel; Resource Sharing; Safety; Schools; Scientist; Surgical Oncologist; T cell therapy; Testing; Therapeutic; Translations; Vaccination; abstracting; base; bench to bedside; cancer immunotherapy; design; efficacy testing; experience; improved; innovation; insight; interest; melanoma; member; novel; novel strategies; novel therapeutic intervention; programs; treatment strategy; tumor microenvironment

Project Summary/Abstract: Immunology and Cancer Immunotherapy (ICI) The overall goal of the Immunology and Cancer Immunotherapy (ICI) Program is to unite the efforts of basic and clinical immunologists to explore the immune system's impact on cancer development and progression, to develop novel strategies that use immunity to treat cancer, and to conduct clinical trials to test novel therapeutics and approaches to improve patient outcomes and increase overall survival. There are twenty-one members from six different academic departments and two professional schools. The current focus and initiatives of the ICI scientists are centered on three themes: Immune regulation, Immune effector mechanisms, and Translational immunotherapy. The immunotherapy approaches are focused on adoptive T cell therapy, vaccination, and immune regulation blockade. While basic research is a key focus, many faculty members actively are involved in translational bench-to-bedside research. Other members are clinicians (hematologists, oncologists or oncologic surgeons) who actively are involved in clinical research and clinical trials. This program joins established and experienced clinical trialists with NCI-funded cancer immunologists to design, execute, and complete Dartmouth-initiated immunotherapy trials in renal cell carcinoma, melanoma, glioblastoma, colorectal carcinoma, multiple myeloma and hematopoietic stem cell transplantation. There are extensive collaborations between ICI members around common areas of interest in immunobiology and immunotherapy, as evidenced by joint publications and funded grants. Major contributions of the program to the mission of the NCCC have been the facilitation of new insights into the tumor microenvironment and how this is affected by leukocytes, the development of novel protein and cell therapies, the translation of Dartmouth investigator ideas into clinical trials, and the accrual of patients to these trials. NCCC has made substantial commitment to improving the depth and breadth of research and clinical translation of the ICI program through support of shared resources, financial awards for new pilot grants, and strategic recruitment of new investigators. More than 280 cancer-related articles have been published over the reporting period, with 46 (16%) appearing in high impact journals. Intra-programmatic publications (43=15%) involved 19 of our 22 members, and inter-programmatic publications (66=24%) involved 15 members. Total grant funding for the program currently is $6.4M, of which $5.5M is peer-reviewed and $2.2M is from NCI.

项目摘要/摘要：免疫学和癌症免疫治疗 (ICI) 免疫学和癌症免疫治疗（ICI）计划的总体目标是联合基础研究人员的努力 和临床免疫学家探索免疫系统对癌症发生和进展的影响， 开发利用免疫治疗癌症的新策略，并进行临床试验来测试新策略 改善患者预后并提高总体生存率的治疗方法和方法。有二十一个 成员来自六个不同的学术部门和两个专业学校。当前的重点和 ICI 科学家的倡议围绕三个主题：免疫调节、免疫效应器 机制和转化免疫疗法。免疫治疗方法主要集中在过继性 T 细胞疗法、疫苗接种和免疫调节阻断。虽然基础研究是重点，但许多教师 成员积极参与从实验室到临床的转化研究。其他成员是临床医生 积极参与临床研究和临床的（血液学家、肿瘤学家或肿瘤外科医生） 试验。该计划将资深且经验丰富的临床试验人员与 NCI 资助的癌症免疫学家联合起来， 设计、执行和完成达特茅斯发起的肾细胞癌、黑色素瘤、 胶质母细胞瘤、结直肠癌、多发性骨髓瘤和造血干细胞移植。有 ICI 成员之间围绕免疫生物学的共同兴趣领域进行广泛合作， 免疫疗法，联合出版物和资助的赠款证明了这一点。该计划的主要贡献 NCCC 的使命是促进对肿瘤微环境的新见解以及如何 这受到白细胞、新型蛋白质和细胞疗法的开发、达特茅斯翻译的影响 将研究者的想法融入临床试验，以及患者对这些试验的参与。 NCCC取得了实质性成果 致力于提高 ICI 项目研究和临床转化的深度和广度 支持共享资源、新试点补助金的财政奖励以及战略性招募新的 调查人员。报告期内已发表 280 多篇癌症相关文章，其中 46 篇 (16%) 出现在高影响力期刊上。程序内出版物 (43=15%) 涉及我们 22 份出版物中的 19 份 成员，跨项目出版物 (66=24%) 涉及 15 名成员。总赠款资金 该计划目前耗资 640 万美元，其中 550 万美元经过同行评审，220 万美元来自 NCI。